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INTRODUCTION 
Heart failure (HF) continues to be an enormous public health problem, despite the many 
advances in its pharmacotherapy over the past 25 years, with a prevalence of 5.7 
million individuals affected and an incidence of over 500,000 new cases annually.1  The 
relevance of the natriuretic peptide (NP) system, particular BNP, is well known in terms 
of HF pathophysiology,2, 3 diagnosis,4 prognosis,5 and therapy.6, 7    However, the full 
impact of testing, and particularly modulating, the NP pathway remains unclear.  Part of 
this difficulty in how to harness this pathway for the benefit of patients is due to 
substantial inter-individual variability in function of the NP pathway.  Not only are the 
optimal diagnostic and prognostic thresholds uncertain and varying,8 but the response 
to extrinsic NP is highly variable with potential for adverse effects and unclear 
therapeutic range.9-11  Better understanding of the variability in this important pathway is 
critical not only because it continues to be explored as a method for personalized 
therapy, but because there are numerous current (nesiritide, carperitide) and 
investigational therapeutics (ularitide,12 CDNP13) targeting it.   
Genetic variation may hold a key to better understanding this individual 
variability.14  BNP levels are known to be heritable,15 and specific genetic variants in NP 
pathway genes have been associated with hypertension,16 BNP level and test 
performance,17, 18 and intracardiac filling pressures,19.  Despite these observations, a 
lack of systematic knowledge remains with respect to the effects of NP genetic 
variability on the production of relevant protein end-products.  Better understanding of 
this variability may allow it to be used to personalize therapy by identifying differences in 
how patients metabolize and respond to NPs.  Relevant to HF, NPs act primarily (Figure 
1) by binding to two membrane-spanning receptors called natriuretic peptide receptor 
(NPR) A and NPRB, which are guanylate cyclases resulting in cyclic guanlyate mono 
phosphate (cGMP) production.  The latter is thought to be the key second messenger 
mediating the NP effects.  Active NP is broken down by neutral endopeptidase (aka 
membrane metallo-endopeptidase (MME)), and taken up by NPRC, another receptor 
which lacks guanylate cyclase function.  These four proteins are produced by the genes 
NPR1, NPR2, MME and NPR3 respectively.  The purpose of this study was to 
systematically study sequence variants in these genes, quantify gene expression and 
protein abundance of each product in relevant human tissue samples in order to 
evaluate important associations. 
 
 
 
 
METHODS 
The study was approved by the Henry Ford Hospital Institutional Review Board.  DNA, 
RNA, and tissue samples from human kidney (n=77) were obtained via the Alvin J. 
Siteman Cancer Center at Washington University School of Medicine and Barnes-
Jewish Hospital in St. Louis, Mo., Tissue Procurement Core lab, under approval from 
Washington University Institutional Review Board and with informed consent.  Kidney 
was chosen as target tissue because each of the four candidate genes and proteins 
(natriuretic peptide receptor (NPR1), NPR2, NPR3 and membrane metallo-
endopeptidase (MME)) are expressed there. 100 samples were originally requested, to 
be distributed evenly among African Americans vs Whites and men vs. women.  In total 
103 suitable samples were tested.   
 
Genotyping, Gene Expression, and Protein Quantitation 
DNA samples were genotyped using a custom Illumina Goldengate 1536-plex 
array which contained candidate-gene coverage relevant to HF including focused 
attention on the four genes of interest. Single nucleotide polymorphisms (SNPs) were 
chosen for the array by attempting to include all coding variants, and then adding all 
non-coding variants to capture alleles with MAF >0.1 prevalence in Caucasians or 
Africans within the gene regions of interest. After processing requirements for the 
Goldengate technology and quality control of genotyping we were left with 118 SNPs in 
the four genes of interest for this study.  Genotyping was auto clustered and then 
individual SNPs were reviewed manually. Call rates for all samples were >90%.  mRNA 
expression was quantified for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
(comparator), NPR1, NPR2, NPR3, and MME using real-time reverse transcriptase 
polymerase chain reaction (RT-PCR) performed in duplicate for each sample. To 
determine the concentration of the protein targets, tissue samples were made into 
lysates and then assayed using double antibody sandwich Enzyme Linked 
Immunosorbant Assays (ELISA). The samples were homogenized by suspending in 1ml 
phosphate buffered saline solution and then sonicated. The resulting suspension was 
centrifuged for 5 minutes at 5000g. The supernatant was then removed and stored at -
80°C for testing. The concentration of each marker was assayed using commercially 
available assay kits (Uscn Life Science Inc., Missouri City, Texas) according to 
manufacturer protocol and using standard curves and software.  Total protein 
concentrations were determined by using a modified Lowry Protein Assay.  The ratio of 
target protein to total protein was reported and tested for association with genotype or 
RNA quantity. 
 
Statistical Analysis 
Following log transformation of the protein and RNA expression data, linear regression 
was used to test for the association of each SNP with RNA and protein quantity under 
an additive genetic model.  A principal components (PC) based method was also used 
to capture the underlying correlation structure within each locus and test the association 
of overall gene variation with RNA and protein quantity. We selected top PCs that 
explain at least 80% of the variation as the gene representation and the PCs were used 
as covariates in the linear regression to test for association of SNPs with RNA and 
protein expression.  All models were adjusted for gender and race.  P values <0.05 
were considered of possible interest in this exploratory study.  To account for multiple 
comparisons we also utilized the method of Hochberg20 and considered findings with 
false discovery rate (FDR) <0.05 significant. 
RESULTS 
Genotype was obtained in 7 loci in NPR1, 18 loci in NPR2, 53 loci in NPR3, and 40 loci 
in MME.  Each site was tested individually for association with RNA and protein quantity 
with summary results shown in Figure 1. In terms of gene expression, several variants 
in MME and NPR3 showed crude associations with unadjusted p<0.05.  For there were 
four SNPs in MME (rs1025192, rs1436630, rs10513469 and rs1816558) and one in 
NPR3 (rs696831) that showed suggestive associations with RNA levels (p≤0.05). 
However, none of these met significance once adjusted for FDR. There were no 
significant associations of genotype with gene expression for NPR1 or NPR2.   
Considering protein quantitation, we assayed each sample for the ratio of specific 
protein of interest (NPR1, NPR2, NPR3, and MME) to total protein, and then tested the 
association of this ratio (i.e. the target protein abundance) with genotypes within the 
corresponding gene.  There were no significant associations of genotype with NPR1 
and protein abundance.  There were two sequence variants in NPR3 (rs696836, 
rs2062708) and one in MME (rs3773895) with significant associations of genotype with 
protein quantity; however these did not withstand adjustment for multiple comparisons. 
Interestingly, eleven SNPs in NPR2 were significantly associated with protein 
expression (p<0.05) and this association persisted after controlling for FDR at 0.05.  
Boxplots of protein abundance by genotype for each significant loci is shown in Figure 
2.  There were no SNPs associated with both RNA and protein expression in any of the 
candidate genes. 
RNA and Protein quantity poorly correlated with each other; NPR1 and MME 
showed weak but statistically significant positive correlations (Pearson’s correlation 
coefficient=0.23 and 0.26, p = 0.04 and 0.03, respectively) while NPR2 and NPR3 did 
not (Figure 3). The PC analyses were broadly consistent with the individual SNP 
analysis above.  PC1 of NPR2 (which accounted for 71% of genetic variability) was the 
only significant association of genetic variation with protein abundance (p=0.04).  The 
factor loadings for PC1 (data not shown) suggest that it is mainly determined by the 
same 11 SNPs above, which each had equally high weight.  We also found an 
association between PC5 of NPR3 and its gene expression (p=0.0084). The loadings of 
SNPs indicates that PC5 is highly contributed by SNPs rs764124, rs1847018, 
rs10057069, rs6889608, rs696831, and rs2302954. 
 
 
 
DISCUSSION  
Our systematic interrogation of genotype, gene expression, and protein quantity 
correlations reveals that genetic variation may play a role in determining protein 
abundance for NPRB.  Interestingly, these associations did not seem to occur via 
changes in gene expression, which did not correlate to either protein quantity or 
genotype for NPR2.  The other genes tested did not show indications of genetic 
variation importantly effecting gene expression or protein abundance in kidney. 
Although there have been numerous studies examining the relationship of NP 
pathway genetic polymorphisms to clinical phenotypes, corresponding functional data is 
less available.  While our study is exploratory and descriptive in nature, these data add 
to the existing knowledgebase by describing the potential physiologic impact of 
candidate variants on gene and protein expression, and prioritizing these for future 
investigation.  These data could be used to buttress the biologic plausibility of previously 
described clinical phenotypes, and in terms of prioritizing variants for subsequent 
clinical interrogation NPR2 appears to be the best target.  While there were some 
interesting genotype: gene expression associations for other pathway candidate genes, 
these did not meet significance and did not correlate to protein abundance.  
There are several limitations of this study that should be considered when 
evaluating these data.  First is the relatively small sample size, limiting the power 
somewhat; for example we estimate 90% power to detect at least 2.5-fold variation and 
minor allele frequency of 0.2.  While high-throughput methods are available for DNA 
sequencing, real-time PCR, and more importantly protein quantification, remain labor 
intensive and impractical for very large sample sizes.  Our sample size was designed to 
accommodate this limitation and indentify robust variation, not very subtle changes in 
protein or gene expression.  Second is that we examined only kidney tissue, and cannot 
deduce information about gene and protein expression in other tissues that may be of 
interest such as cardiac tissue.  However, kidney was felt to be the best choice when 
considering the NP pathway physiologically, and as it pertains to pharmaceuticals (such 
as recombinant NPs or endopeptidase inhibitors), because it is a key location for both 
clearance and effect of NPs, and there is expression of all the candidate genes.  
Another potential concern is that renal tissue is not homogenous; how whether and how 
this impacted on our findings is unknown.  Finally, we have focused on protein 
quantitation and have not tested protein function.  This remains important investigation 
for follow up studies.
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FIGURE LEGENDS 
Figure 1. Graphical presentation of p-values for testing SNP association with gene 
expression and protein expression for NPR1, NPR2, NPR3, MME 
Figure 2. Target protein abundance by genotype in the 11 statistically significant SNPs 
of NPR2 (FDR≤0.05). 
Figure 3. Scatter plot showing the relation between RNA and protein quantity for each 
gene. 
Figure 1. 
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Figure 2. Target protein abundance by genotype for NPR2 (loci with FDR≤0.05). (0,1,2) 
represents the additive coding of the number of copies of the minor allele.  
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Figure 3. Scatter plot showing the relation between RNA and protein quantity for each 
gene. Solid curve represents the smooth fit to better visualize the trends. The fit was 
generated using locally weighted scatter plot smoother (LOWESS).  
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